25856-01-3

Basic information

• Product Name: 1-(4-bromophenyl)-3-phenylpropane-1,3-dione
• Synonyms: 1-(4-bromophenyl)-3-phenylpropane-1,3-dione;1-(4-Bromophenyl)-3-phenyl-1,3-propanedione
• CAS NO: 25856-01-3
• Molecular Formula: C₁₅H₁₁BrO₂
• Molecular Weight: 303.15064
• Mol File: 25856-01-3.mol
• Article Data: 15

Chemical Properties

• Melting Point: 94 °C
• Boiling Point: 443.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.422±0.06 g/cm3(Predicted)
• PKA: 8.66±0.12(Predicted)
• CAS DataBase Reference: 1-(4-bromophenyl)-3-phenylpropane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromophenyl)-3-phenylpropane-1,3-dione(25856-01-3)
• EPA Substance Registry System: 1-(4-bromophenyl)-3-phenylpropane-1,3-dione(25856-01-3)

Safety Data

• Hazardous Substances Data: 25856-01-3(Hazardous Substances Data)

Usage

Description

1-(4-bromophenyl)-3-phenylpropane-1,3-dione, also known as bromadoline, is a chemical compound with the molecular formula C15H11BrO2. It is a derivative of the medicine-based compound phenylpropanone and is commonly used in the production of pharmaceutical drugs. Bromadoline is known for its analgesic and sedative effects, making it a valuable ingredient in pain medications and sedatives. However, due to its potential for abuse and addiction, the use and distribution of bromadoline is highly regulated in many countries. It is important to handle this chemical with caution and under the supervision of a trained professional.

Uses

Used in Pharmaceutical Industry:
1-(4-bromophenyl)-3-phenylpropane-1,3-dione is used as an active pharmaceutical ingredient for its analgesic and sedative properties, contributing to the development of pain medications and sedatives.
Used in Pain Management:
Bromadoline is used as an analgesic agent for managing pain due to its effectiveness in reducing discomfort and alleviating pain sensations.
Used in Sedation:
As a sedative, 1-(4-bromophenyl)-3-phenylpropane-1,3-dione is used to induce a state of calmness and relaxation, which can be beneficial in various medical procedures and treatments requiring sedation.
Note: The use of bromadoline in these applications is subject to strict regulations and professional oversight due to its potential for abuse and addiction.

Upstream product

• 861381-68-2 2-bromo-3,3-dimethoxy-1,3-diphenyl-propan-1-one 
• 67-56-1 methanol 
• 64-19-7 acetic acid 
• 93-58-3 benzoic acid methyl ester 
• 99-90-1 para-bromoacetophenone 
• 57699-28-2 methyl 4-bromophenylglyoxalate 
• 70-11-1 α-bromoacetophenone 
• 23565-63-1 1-(4-bromophenyl)-3-phenylpropynone 
• 39833-48-2 3-(4-bromophenyl)-1-phenylprop-2-yn-1-one 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 98-86-2 acetophenone 
• 586-76-5 4-Bromobenzoic acid 
• 932-90-1 Benzaldoxime 
• 15206-55-0 methyl 2-oxo-2-phenylacetate 

Downstream Products

• 57736-15-9 2-(4'-bromophenyl)-3-benzoyl-4-phenyl-1-oxa-4-azabutadiene 
• 1045345-88-7 2-[1-(4-methoxylphenyl)-3-phenyl-2-propynyl]-1-(4-bromophenyl)-3-phenyl-1,3-propanedione 
• 39229-12-4 4-bromobenzil 
• 1417818-39-3 1-(4-bromo-phenyl)-2-phenyl-ethane-1,2-diol 
• 53573-22-1 5-(p-bromophenyl)-3-phenyl-2-isoxazole 
• 53573-21-0 3-(4-bromophenyl)-5-phenylisoxazole 
• 65182-59-4 2-(4'-bromophenyl)-1,8-naphthyridine 
• 116625-83-3 (4-Bromo-phenyl)-(2-phenyl-[1,8]naphthyridin-3-yl)-methanone 
• 93944-86-6 2-bromo-1-(4-bromophenyl)-3-phenyl-1,3-propanedione 
• 61668-27-7 (+/-)-2-benzoyl-1-(4-bromo-phenyl)-4-phenyl-butane-1,4-dione 
• 586-76-5 4-Bromobenzoic acid 
• 61668-32-4 2-benzoyl-1-(4-bromophenyl)pentane-1,4-dione 

Relevant articles and documents

Non-metal catalytic method for preparing 1,3-diketone compounds based on acetyenic ketone

The invention discloses a non-metal catalytic method for preparing 1,3-diketone compounds based on acetyenic ketone. The preparation method is a stepwise method or a one-pot method. The stepwise method comprises the following steps: mixing an acetyenic ketone compound I, a nitrogen-containing aromatic compound II and a No.1 base for a reaction, performing separation and purification to obtain an intermediate product, mixing the intermediate product and a No.2 base for a reaction, and performing separation and purification to obtain the product; and the one-pot method comprises the following steps: firstly mixing an acetyenic ketone compound I and a nitrogen-containing aromatic compound II, adding a No.1 base, performing a reaction for a period of time, adding a No.2 base, continuing a reaction for a period of time, and finally performing separation and purification to obtain the product. The method provided by the invention has mild reaction conditions, simple operation and a higher yield, wherein the yield is generally 80% or more, and the method has greater practical application value in drug synthesis.

Analyzing the Relation between Structure and Aggregation Induced Emission (AIE) Properties of Iridium(III) Complexes through Modification of Non-Chromophoric Ancillary Ligands

Unconventionally modified dibenzoylmethane (dbm) ligands have been synthesized and successfully utilized as ancillary ligands for neutral iridium(III) complexes of the formula [Ir(dFppy)2(LX)], where dFppyH is 2-(2,4-difluorophenyl)pyridine and LX is tribenzoylmethane (tbm) or 1-phenyl-3-(4-(pyridin-2-yl)phenyl)propane-1,3-dione (pydbm). The modification of the ligands aims to prevent or enhance possible intermolecular interactions between the dFppy and/or the LX moiety in comparison with the previously reported [Ir(dFppy)2(dbm)] complex. The aggregation induced emission (AIE) properties of these complexes are significantly modulated, as a consequence of the different π–π interactions revealed by X-ray crystallography.

Synthesis and photophysical properties of halogenated derivatives of (dibenzoylmethanato)boron difluoride

A series of (dibenzoylmethanato)boron difluoride (BF2DBM) derivatives with a halogen atom in one of the phenyl rings at the para-position were synthesized and used to elucidate the effects of changing the attached halogen atom on the photophysi